LakePharma Announces Dedicated Vector Center to Support Gene and Cell TherapyAdded On: 2019-02-26
LakePharma Announces its GMP Biorepository Facility near Boston is Now Operational, Plans Additional HiringAdded On: 2019-01-15
LakePharma announces its cGMP microBiomanufacturing Center is now operationalAdded On: 2018-12-18
Added On: 2018-04-26
Salt Lake City, UT, USA and South San Francisco, CA, USA, April 26th 2018. Carterra™ Inc., a provider of innovative drug discovery technology, and LakePharma a leading biologics contract development and manufacturing organization (CDMO), announced today that LakePharma has purchased a Carterra LSA™, a fully automated, label-free, high-throughput monoclonal antibody (mAb) characterization instrument.
LakePharma will use the LSA instrument to further expand and support its growing contract biotherapeutics discovery research business. The LSA is unique in that it provides the mAb characterization throughput and functionality that matches the output from the state-of-the-art antibody expression platforms utilized by LakePharma. This enables all antibodies to be rapidly and comprehensively screened early in the discovery process so that unique epitopes and potential novel therapeutic candidates can be identified, thereby expanding and enhancing IP coverage. Integrating the LSA into its processes will increase the speed, data out-put and productivity of LakePharma’s biotherapeutics service offering, thereby delivering enhanced value to its customers.
“LakePharma is the first CDMO to embed Carterra’s LSA instrument into their service business,” said Josh Eckman, CEO Carterra. “The high throughput, flow-based kinetics and comprehensive epitope binning capabilities of the LSA coupled with our powerful data analysis and visualization software will enable LakePharma to provide a new level of mAb discovery service to their clients.”
Dr. Aaron Sato, CSO LakePharma added, “The industry-leading, high-throughput surface plasmon resonance LSA instrument will enable us to thoroughly curate the unique antibodies from our phage display and hybridoma campaigns.” He continued,
“LakePharma will now offer stand-alone CRO services on the LSA platform as a fee-for-service, and importantly, when combined with our comprehensive antibody technology offerings, the Carterra LSA platform will enhance all our client discovery projects. We are so excited to start using it.”
About Carterra Inc.
Carterra™ is a leading provider of innovative technology designed to accelerate the discovery of novel therapeutic candidates. Carterra’s high throughput LSA™ instrument for monoclonal antibody (mAb) discovery and characterization combines patented microfluidics technology with real-time array Surface Plasmon Resonance (SPR) and industry leading data analysis and visualization software, delivering 100x the throughput in 10% of the time while using only 1% of the sample compared to existing platforms. The LSA provides customers with the mAb characterization throughput and functionality that matches the output from state-of-the-art antibody expression platforms. This enables all antibodies to be rapidly and comprehensively screened early in the discovery process so that unique epitopes and potential novel therapeutic candidates can be identified, while expanding and enhancing IP coverage.